c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer.

MLA

Nebbioso, Angela, et al. “C-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 23, no. 10, May 2017, pp. 2542–55. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-15-2388.

APA

Nebbioso, A., Carafa, V., Conte, M., Tambaro, F. P., Abbondanza, C., Martens, J., Nees, M., Benedetti, R., Pallavicini, I., Minucci, S., Garcia-Manero, G., Iovino, F., Lania, G., Ingenito, C., Belsito Petrizzi, V., Stunnenberg, H. G., & Altucci, L. (2017). c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 23(10), 2542–2555. https://doi.org/10.1158/1078-0432.CCR-15-2388

Chicago

Nebbioso, Angela, Vincenzo Carafa, Mariarosaria Conte, Francesco Paolo Tambaro, Ciro Abbondanza, Joost Martens, Matthias Nees, et al. 2017. “C-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 23 (10): 2542–55. doi:10.1158/1078-0432.CCR-15-2388.